The Glycan Shield of the SARS-Cov-2 Spike; Antigenicity and Function

NIH Pandemic-Era Grants

Pandemic Era Grants

2021

↗ Live URL (may be dead)

Document text

Principal Investigator: JAMES L ARTHOS
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2021
Award: $92,584
Funding agency: National Institute of Allergy and Infectious Diseases

We have produced various versions of a recombinant SARS-CoV-2 Spike glycoproteins that differ in their glycan content. We then characterized the way in which these differentially glycosylated forms of the spike interact with ACE2, and various lectin receptors (e.g L-SIGN, DC-SIGN). In addition, we are compared the reactivity of these spikes with sera from convalescent Covid-19+ subjects. Regarding pre-existing cross-reactive anti spike antibody responses, we identified cross reactive antibody responses in serum samples derived from individuals in the U.S, Thailand, and Uganda. The frequency and pattern of these responses differed among these three cohorts. These findings may help explain differences in the way the pandemic is evolving in these three countries.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><ACE2><Antibodies><Antibody Response><Blood Serum><CD209><CD209 gene><CDSIGN><COVID-19><COVID-19 S protein><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 therapeutics><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 S protein><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 therapeutics><COVID19 vaccine><COVID19 virus><CV-19><CV19><Carbohydrates><CoV-2><CoV2><Complex><Country><D-Mannose><DC-SIGN><DC-SIGN1><Dendritic Cells><Development><Epithelial Cells><Evaluation><Frequencies><Glycans><Glycoproteins><Individual><Lectin Receptors><Link><Mannopyranose><Mannopyranoside><Mannose><Metabolic Glycosylation><Pattern><Polysaccharides><Receptor Protein><Recombinants><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 therapeutics><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 therapeutics><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Serum><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 therapeutics><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Site><Structure><Thailand><Therapeutic Agents><Uganda><Veiled Cells><Wuhan coronavirus><angiotensin converting enzyme 2><angiotensin converting enzyme II><cohort><corona virus disease 2019><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 therapeutics><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><cross reactivity><developmental><glycosylation><hCoV19><nCoV2><pandemic><pandemic disease><receptor><response><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><therapeutics against COVID-19><therapeutics against COVID19><therapeutics against SARS-CoV-2><therapeutics against SARS-coronavirus-2><therapeutics against Severe acute respiratory syndrome coronavirus 2><therapeutics against coronavirus disease 2019><therapeutics for novel coronavirus><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus>